Biotie Therapies Corp (BTH1V.HE) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biotie Therapies Oyj decides not to exercise option to acquire Neurelis Inc but retains economic interest in future success of NRL-1


Friday, 11 Jul 2014 02:01am EDT 

Biotie Therapies Oyj:Decides not to exercise option to acquire Neurelis, Inc. but retains economic interest in future success of NRL-1. 

Company Quote

0.289
 --
11:29am EDT